India Biosimilar Market Overview

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Growth Rate: 17.38% (2025-2033)

India biosimilar industry is growing at a rapid pace owing to the rising demand for affordable biologics and favorable regulation. Research and development and manufacturing are also fueling market growth. According to the latest report by IMARC Group, the India biosimilar market size reached USD 866.2 million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,662.9 million by 2033, exhibiting a growth rate (CAGR) of 17.38% during 2025-2033.

Download a sample copy of the Report: https://www.imarcgroup.com/india-biosimilar-market/requestsample

India Biosimilar Trends and Drivers:

Biosimilars provide a cheaper option to costly originator biologics. More people now have chronic diseases. This includes diabetes, cancer, and autoimmune disorders. The patient population is large and growing. The Indian government supports market growth with policies like the National Biopharma Mission. They also have made regulatory pathways easier. Local drug makers like Biocon, Dr. Reddy’s, and Intas Pharmaceuticals are taking the lead. They use their skills in generics to create high-quality biosimilars. India's strong manufacturing skills and low prices make it a key player in the global biosimilar market. Exports to regulated markets like the U.S. and Europe are also rising. Challenges still exist, like strict quality standards, complicated manufacturing, and intellectual property problems. These issues need ongoing innovation and investment in R&D to keep growing.

A key trend in the Indian biosimilar market is the rising interest in monoclonal antibodies (mAbs) and oncology biosimilars. These two areas make up a large part of the pipeline. Cancer rates are increasing. Biosimilars for drugs like trastuzumab and rituximab are becoming popular. They give patients access to life-saving treatments at a much lower cost. Partnerships between Indian firms and multinationals are growing. This helps with technology transfer and expands market reach. More public healthcare programs, like Ayushman Bharat, are using biosimilars. This is boosting demand. Advancements in biomanufacturing are boosting efficiency and cutting costs. This includes using single-use technologies and continuous processing. Even with these improvements, many doctors and patients still lack awareness about biosimilars. This calls for focused education campaigns. The India biosimilar market is set for steady growth. This growth comes from innovation, affordability, and smart partnerships. These factors make it an important part of global healthcare access.

We explore the factors propelling the India biosimilar market growth, including technological advancements, consumer behaviors, and regulatory changes.

India Biosimilar Industry Segmentation:

The report has segmented the market into the following categories:

Molecule Insights:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

Indication Insights:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

Manufacturing Type Insights:

• In-house Manufacturing
• Contract Manufacturing

Regional Insights:

• North India
• West and Central India
• South India
• East and Northeast India

Competitive Landscape:

The competitive landscape of the industry has also been examined, along with the profiles of the key players.

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current, and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: [email protected] 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145